Abstracts Featuring clonoSEQ®
66th American Society of Hematology Annual Meeting & Exposition
Updated: December 2, 2024

Abstract	Title	Presentation Timing (PT)
Late-Breaking Presentation		
Mantle Cell Lymphoma		
LBA6	Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial	Tuesday, December 10, 2024, 7:30-9 A.M.
Oral Presentations		
Acute Lymphoblastic Leukemia		
1 (Plenary session)	Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children's Oncology Group Study AALL1731	Sunday, December 8, 2024, 2-4 P.M.
679	Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL	Sunday, December 8, 2024, 4:30-6 P.M.
727	Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features	Monday, December 9, 2024, 10:30 A.M.-12 P.M.
837	Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse	Monday, December 9, 2024, 3:15-4:45 P.M.
924	TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial	Monday, December 9, 2024, 4-5:30 P.M.
963	Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes	Monday, December 9, 2024, 5-6:30 P.M.

966	CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study	Monday, December 9, 2024, 5:45-7:15 P.M.
Multiple Myeloma		
93	A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma	Saturday, December 7, 2024, 10-11:30 A.M.
362	Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial	Saturday, December 7, 2024, 4:15-5:45 P.M.
363	Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation	Saturday, December 7, 2024, 4:30-6 P.M.
487	Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study	Sunday, December 8, 2024, 9:30-11 A.M.
497	Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis	Sunday, December 8, 2024, 10:30-12 P.M.
675	Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups	Sunday, December 8, 2024, 5-6:30 P.M.
770	Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study	Monday, December 9, 2024, 10:45 A.M.-12:15 P.M.
772	Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial	Monday, December 9, 2024, 11:15 A.M.-12:45 P.M.

1031	Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial	Monday, December 9, 2024, 5:30-7 P.M.
1032	Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial	Monday, December 9, 2024, 5:45-7:15 P.M.
Mantle Cell Lymphoma		
236	Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181	Saturday, December 7, 2024, 2:15-3:45 P.M.
746	MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naive Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses	Monday, December 9, 2024, 10:45 A.M.-12:15 P.M.
750	Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naive Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease	Monday, December 9, 2024, 11:45 A.M.-1:15 P.M.
Follicular Lymphoma		
342	Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial	Saturday, December 7, 2024, 5:15-6:45 P.M.
Chronic Lymphocytic Leukemia		
883	Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1	Monday, December 9, 2024, 2:45-4:15 P.M.
887	Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study	Monday, December 9, 2024, 3:45-5:15 P.M.

1010	Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)	Monday, December 9, 2024, 4:45-6:15 P.M.
1011	Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)	Monday, December 9, 2024, 5-6:30 P.M.
Smoldering Multiple Myeloma		
1027	Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma	Monday, December 9, 2024, 4:30-6 P.M.
Poster Presentations		
Acute Lymphoblastic Leukemia		
1427	Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic TransplantClinically Relevant Abstract	Saturday, December 7, 2024, 5:30-7:30 P.M.
1432	Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)	Saturday, December 7, 2024, 5:30-7:30 P.M.
1439	Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia	Saturday, December 7, 2024, 5:30-7:30 P.M.
1441	Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update	Saturday, December 7, 2024, 5:30-7:30 P.M.
1450	Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant	Saturday, December 7, 2024, 5:30-7:30 P.M.
1465	Clearance of Very Low Levels of Measurable Residual Disease with Blinatumomab Significantly Improves Outcomes in B-Cell Acute Lymphoblastic Leukemia	Saturday, December 7, 2024, 5:30-7:30 P.M.
2837	Enhanced Flow Cytometry and Next Generation Sequencing Assays for Residual B Lymphoblastic Leukemia (B-ALL) Reveal a Subset with Discordant Results Due to Leukemic Changes Post-Therapy	Sunday, December 8, 2024, 6-8 P.M.

3470	Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform	Sunday, December 8, 2024, 6-8 P.M.
4194	Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update	Monday, December 9, 2024, 6-8 P.M.
4200	NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival	Monday, December 9, 2024, 6-8 P.M.
4202	Concurrent Blinatumomab and Human Leukocyte Antigen-Mismatched Cellular Therapy in Patients with High-Risk B-Cell Acute Lymphoblastic Leukemia, a Phase I Prospective Cohort Study	Monday, December 9, 2024, 6-8 P.M.
Mantle Cell Lymphoma		
1626	High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma	Saturday, December 7, 2024, 5:30-7:30 P.M.
1631	Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study	Saturday, December 7, 2024, 5:30-7:30 P.M.
1633	Acalabrutinib, Umbralisib and Ublituximab Regimen (AU2) Demonstrates High Response Rate and Undetectable Molecular Minimal Residual Disease (MRD) in Patients (pts) with De Novo Mantle Cell Lymphoma (MCL)	Saturday, December 7, 2024, 5:30-7:30 P.M.
3038	Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma	Sunday, December 8, 2024, 6-8 P.M.
4408	Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)	Monday, December 9, 2024, 6-8 P.M.
Diffuse Large B-Cell Lymphoma		
1737	Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial	Saturday, December 7, 2024, 5:30-7:30 P.M.
4480	3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma	Monday, December 9, 2024, 6-8 P.M.

Chronic Lymphocytic Leukemia		
1865	Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease	Saturday, December 7, 2024, 5:30-7:30 P.M.
1867	Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naive Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)	Saturday, December 7, 2024, 5:30-7:30 P.M.
1871	First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis	Saturday, December 7, 2024, 5:30-7:30 P.M.
4633	Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004	Monday, December 9, 2024, 6-8 P.M.
Multiple Myeloma		
1976	Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study	Saturday, December 7, 2024, 5:30-7:30 P.M.
3359	Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial	Sunday, December 8, 2024, 6-8 P.M.
3365	Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial	Sunday, December 8, 2024, 6-8 P.M.
3373	Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study	Sunday, December 8, 2024, 6-8 P.M.

3388	Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up	Sunday, December 8, 2024, 6-8 P.M.
3784	Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma	Sunday, December 8, 2024, 6-8 P.M.
4731	Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide	Monday, December 9, 2024, 6-8 P.M.
4756	High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus IsaRd in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)	Monday, December 9, 2024, 6-8 P.M.
5028	MRD Testing in Multiple Myeloma: Modeling the Potential Clinical and Economic Outcomes Based on the Master Trial	Monday, December 9, 2024, 6-8 P.M.
Other		
2838	Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages	Sunday, December 8, 2024, 6-8 P.M.
Follicular Lymphoma		
2958	Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study	Sunday, December 8, 2024, 6-8 P.M.
3034	Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update	Sunday, December 8, 2024, 6-8 P.M.
Chronic Lymphocytic Leukemia		
3237	CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations	Sunday, December 8, 2024, 6-8 P.M.

3247	Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination by clonoSEQ®	Sunday, December 8, 2024, 6-8 P.M.
AL Amyloidosis		
3302	Minimal Residual Disease Testing in Relapsed Systemic AL Amyloidosis	Sunday, December 8, 2024, 6-8 P.M.
3304	Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Light Chain Amyloidosis	Sunday, December 8, 2024, 6-8 P.M.
Smoldering Multiple Myeloma		
3360	Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma	Sunday, December 8, 2024, 6-8 P.M.